Effects of chronic perphenazine treatment on growth and endocrine function in developing rats

G. H. Greeley, M. A. Lipton, J. S. Kizer

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    To study the possible adverse effects of chronic perphenazine treatment upon growth and endocrine function in a developing animal, perphenazine (1, 10 and 25 mg/kg b.wt.) was administered to developing rats. At various intervals, body weight, naso-anal length, age at vaginal opening, number of regular estrous cycles and serum levels of follicle-stimulating hormone, luteinizing hormone, growth hormone, thyroid-stimulating hormone, prolactin, 3,5,3'-triiodothyronine and thyroxine were measured. 1) At 10 and 25 mg/kg b.wt., perphenazine significantly decreases rate of skeletal growth and body weight gain in male and female rats, primarily due to a decreased food and water intake. 2) No dose of chronic perphenazine (1, 10 or 25 mg/kg b.wt.) significantly delays vaginal patency or the age of initiation of vaginal estrus or proestrus. The age at initiation of the first regular estrous cycle, however, is significantly delayed. 3) Estrous cycles continue to be abnormal 3 months after cessation of perphenazine treatment. 4) Serum levels of 3,5,3'-triiodothyronine and thyroxine are significantly depressed in 10 and 25 mg/kg b.wt. perphenazine-treated male and female rats. 5) Serum prolactin is significantly higher in 10 and 25 mg/kg b.wt. perphenazine-treated rats. 6) Chronic perphenazine treatment (1, 10 and 25 mg/kg b.wt.) significantly increases serum thyroid-stimulating hormone levels in females, with no significant effect in male rats. 7) In males and females, chronic perphenazine treatment has no consistent effect on serum levels of luteinizing hormone, follicle-stimulating hormone or growth hormone. Thirty to 60 days after cessation of perphenazine treatment, serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, 3,5,3'-triiodothyronine and thyroxine are normal. In conclusion, chronic perphenazine treatment during the neonatal period can significantly interfere with normal growth and endocrine function. Most of these effects, with the exception of the irregular estrous cycles, disappear after discontinuation of perphenazine administration.

    Original languageEnglish (US)
    Pages (from-to)133-138
    Number of pages6
    JournalJournal of Pharmacology and Experimental Therapeutics
    Volume220
    Issue number1
    StatePublished - 1982

    Fingerprint

    Perphenazine
    Growth
    Estrous Cycle
    Follicle Stimulating Hormone
    Triiodothyronine
    Thyrotropin
    Therapeutics
    Luteinizing Hormone
    Serum
    Thyroxine
    Prolactin
    Withholding Treatment
    Growth Hormone
    Body Weight
    Proestrus
    Estrus
    Drinking
    Weight Gain

    ASJC Scopus subject areas

    • Pharmacology

    Cite this

    Effects of chronic perphenazine treatment on growth and endocrine function in developing rats. / Greeley, G. H.; Lipton, M. A.; Kizer, J. S.

    In: Journal of Pharmacology and Experimental Therapeutics, Vol. 220, No. 1, 1982, p. 133-138.

    Research output: Contribution to journalArticle

    @article{672369ad8b074070b5014e80e28488a4,
    title = "Effects of chronic perphenazine treatment on growth and endocrine function in developing rats",
    abstract = "To study the possible adverse effects of chronic perphenazine treatment upon growth and endocrine function in a developing animal, perphenazine (1, 10 and 25 mg/kg b.wt.) was administered to developing rats. At various intervals, body weight, naso-anal length, age at vaginal opening, number of regular estrous cycles and serum levels of follicle-stimulating hormone, luteinizing hormone, growth hormone, thyroid-stimulating hormone, prolactin, 3,5,3'-triiodothyronine and thyroxine were measured. 1) At 10 and 25 mg/kg b.wt., perphenazine significantly decreases rate of skeletal growth and body weight gain in male and female rats, primarily due to a decreased food and water intake. 2) No dose of chronic perphenazine (1, 10 or 25 mg/kg b.wt.) significantly delays vaginal patency or the age of initiation of vaginal estrus or proestrus. The age at initiation of the first regular estrous cycle, however, is significantly delayed. 3) Estrous cycles continue to be abnormal 3 months after cessation of perphenazine treatment. 4) Serum levels of 3,5,3'-triiodothyronine and thyroxine are significantly depressed in 10 and 25 mg/kg b.wt. perphenazine-treated male and female rats. 5) Serum prolactin is significantly higher in 10 and 25 mg/kg b.wt. perphenazine-treated rats. 6) Chronic perphenazine treatment (1, 10 and 25 mg/kg b.wt.) significantly increases serum thyroid-stimulating hormone levels in females, with no significant effect in male rats. 7) In males and females, chronic perphenazine treatment has no consistent effect on serum levels of luteinizing hormone, follicle-stimulating hormone or growth hormone. Thirty to 60 days after cessation of perphenazine treatment, serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, 3,5,3'-triiodothyronine and thyroxine are normal. In conclusion, chronic perphenazine treatment during the neonatal period can significantly interfere with normal growth and endocrine function. Most of these effects, with the exception of the irregular estrous cycles, disappear after discontinuation of perphenazine administration.",
    author = "Greeley, {G. H.} and Lipton, {M. A.} and Kizer, {J. S.}",
    year = "1982",
    language = "English (US)",
    volume = "220",
    pages = "133--138",
    journal = "Journal of Pharmacology and Experimental Therapeutics",
    issn = "0022-3565",
    publisher = "American Society for Pharmacology and Experimental Therapeutics",
    number = "1",

    }

    TY - JOUR

    T1 - Effects of chronic perphenazine treatment on growth and endocrine function in developing rats

    AU - Greeley, G. H.

    AU - Lipton, M. A.

    AU - Kizer, J. S.

    PY - 1982

    Y1 - 1982

    N2 - To study the possible adverse effects of chronic perphenazine treatment upon growth and endocrine function in a developing animal, perphenazine (1, 10 and 25 mg/kg b.wt.) was administered to developing rats. At various intervals, body weight, naso-anal length, age at vaginal opening, number of regular estrous cycles and serum levels of follicle-stimulating hormone, luteinizing hormone, growth hormone, thyroid-stimulating hormone, prolactin, 3,5,3'-triiodothyronine and thyroxine were measured. 1) At 10 and 25 mg/kg b.wt., perphenazine significantly decreases rate of skeletal growth and body weight gain in male and female rats, primarily due to a decreased food and water intake. 2) No dose of chronic perphenazine (1, 10 or 25 mg/kg b.wt.) significantly delays vaginal patency or the age of initiation of vaginal estrus or proestrus. The age at initiation of the first regular estrous cycle, however, is significantly delayed. 3) Estrous cycles continue to be abnormal 3 months after cessation of perphenazine treatment. 4) Serum levels of 3,5,3'-triiodothyronine and thyroxine are significantly depressed in 10 and 25 mg/kg b.wt. perphenazine-treated male and female rats. 5) Serum prolactin is significantly higher in 10 and 25 mg/kg b.wt. perphenazine-treated rats. 6) Chronic perphenazine treatment (1, 10 and 25 mg/kg b.wt.) significantly increases serum thyroid-stimulating hormone levels in females, with no significant effect in male rats. 7) In males and females, chronic perphenazine treatment has no consistent effect on serum levels of luteinizing hormone, follicle-stimulating hormone or growth hormone. Thirty to 60 days after cessation of perphenazine treatment, serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, 3,5,3'-triiodothyronine and thyroxine are normal. In conclusion, chronic perphenazine treatment during the neonatal period can significantly interfere with normal growth and endocrine function. Most of these effects, with the exception of the irregular estrous cycles, disappear after discontinuation of perphenazine administration.

    AB - To study the possible adverse effects of chronic perphenazine treatment upon growth and endocrine function in a developing animal, perphenazine (1, 10 and 25 mg/kg b.wt.) was administered to developing rats. At various intervals, body weight, naso-anal length, age at vaginal opening, number of regular estrous cycles and serum levels of follicle-stimulating hormone, luteinizing hormone, growth hormone, thyroid-stimulating hormone, prolactin, 3,5,3'-triiodothyronine and thyroxine were measured. 1) At 10 and 25 mg/kg b.wt., perphenazine significantly decreases rate of skeletal growth and body weight gain in male and female rats, primarily due to a decreased food and water intake. 2) No dose of chronic perphenazine (1, 10 or 25 mg/kg b.wt.) significantly delays vaginal patency or the age of initiation of vaginal estrus or proestrus. The age at initiation of the first regular estrous cycle, however, is significantly delayed. 3) Estrous cycles continue to be abnormal 3 months after cessation of perphenazine treatment. 4) Serum levels of 3,5,3'-triiodothyronine and thyroxine are significantly depressed in 10 and 25 mg/kg b.wt. perphenazine-treated male and female rats. 5) Serum prolactin is significantly higher in 10 and 25 mg/kg b.wt. perphenazine-treated rats. 6) Chronic perphenazine treatment (1, 10 and 25 mg/kg b.wt.) significantly increases serum thyroid-stimulating hormone levels in females, with no significant effect in male rats. 7) In males and females, chronic perphenazine treatment has no consistent effect on serum levels of luteinizing hormone, follicle-stimulating hormone or growth hormone. Thirty to 60 days after cessation of perphenazine treatment, serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin, thyroid-stimulating hormone, 3,5,3'-triiodothyronine and thyroxine are normal. In conclusion, chronic perphenazine treatment during the neonatal period can significantly interfere with normal growth and endocrine function. Most of these effects, with the exception of the irregular estrous cycles, disappear after discontinuation of perphenazine administration.

    UR - http://www.scopus.com/inward/record.url?scp=0020065443&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0020065443&partnerID=8YFLogxK

    M3 - Article

    C2 - 6796671

    AN - SCOPUS:0020065443

    VL - 220

    SP - 133

    EP - 138

    JO - Journal of Pharmacology and Experimental Therapeutics

    JF - Journal of Pharmacology and Experimental Therapeutics

    SN - 0022-3565

    IS - 1

    ER -